We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Hematological Biomarkers Predict Prognosis in Hepatocellular Carcinoma

By LabMedica International staff writers
Posted on 12 Oct 2020
Hepatocellular carcinoma (HCC) is an inflammation-related cancer, where non-resolving inflammation contributes to its development and progression. More...
Peripheral inflammatory cells have been shown to be associated with the prognosis of various types of cancer.

Immune cells conduct their functions in the tumor microenvironment, and in the peripheral blood to promote metastasis The quantification of peripheral blood inflammatory cells such as neutrophils, lymphocytes, monocytes, and platelets, as well as their ratios, have been identified and validated as novel biomarkers with prognostic significance in several cancers.

A team of hepatologists at the Pusan National University School of Medicine (Yangsan, Republic of Korea) and their associate retrospectively analyzed 1,681 patients with HCC who were newly diagnosed between November 2008 and March 2018. Included in the study were 1,335 (79.4%) males and 346 (20.6%) females. The patients ranged in age from 27 to 88 years, and the median age was 60 years. Hepatitis B, hepatitis C, and alcoholic liver disease were diagnosed in 1,039 (61.8%), 279 (16.6%), and 184 (11.0%) patients, respectively. The frequency of patients with underlying liver cirrhosis was 85.1%.

All pretreatment routine blood cell examinations that were performed within two weeks before treatment were used for the analysis. Overall survival (OS) was calculated from the date of HCC diagnosis to the date of death or last follow-up. OS was compared for between patients with high and low neutrophils, lymphocytes, and monocytes (dichotomized by median values).

The scientist used univariate and multivariate analyses, and found that individual neutrophil, lymphocyte and monocyte cell counts were independent indicators of poor OS. High neutrophil (≥3100 × 106/L) and, monocyte (≥470 × 106/L) counts and low lymphocyte counts (< 1640 × 106/L) significantly associated with reduced OS. Neutrophil and, monocyte cell counts rose and lymphocyte counts decreased in association with advancing the Barcelona Clinic Liver Cancer stage.

The team also analyzed the combination score and found that higher neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and lower lymphocyte to monocyte ratio (LMR) had worse OS. Patients with high neutrophils and monocytes were more likely to have larger tumor size. The presence of vascular invasion was associated with high neutrophil and, monocyte counts and with low lymphocyte counts. High neutrophils and monocyte counts were associated with extrahepatic metastasis.

The authors concluded that pretreatment peripheral neutrophils, lymphocytes, and monocytes are independently associated with outcomes of patients with HCC. These cells provide a noninvasive, low-cost, easy, and reproducible biomarker that can be used in routine clinical practice to predict the prognosis of patients with HCC. The study was published on September 29, 2020 in the journal BMC Cancer.

Related Links:
Pusan National University School of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
Portable POCT Blood Gas Analyzer
BD100
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical Abstract (Ziegler, AG., Rewers, M.J., Achenbach, P. et al. Diabetologia (2026). https://doi.org/10.1007/s00125-026-06841-z)

International Consensus Guidance Outlines General Population Screening for Early-Stage Type 1 Diabetes

Type 1 diabetes (T1D) is an autoimmune disease that can develop in childhood or adulthood and affects an estimated 9.5 million people worldwide. Its complications range from acute diabetic ketoacidosis... Read more

Microbiology

view channel
Image: The current BDBV outbreak in the DRC underscores response challenges for rare, severe infections (Image Credit: 123RF)

Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics

Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read more

Technology

view channel
Image: The 5811 R retains the performance and versatility of its predecessor while adding a new design, a refreshed user interface, and updated sustainable cooling technology. (Photo courtesy of Eppendorf)

New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling

Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more

Industry

view channel
Image: The combined offering is designed to streamline workflows and support multicolor applications used in leukemia, lymphoma, and measurable residual disease assessment in specialized clinical settings

Sysmex and Cytek Collaboration Expands Access to Advanced Clinical Flow Cytometry

Sysmex Europe SE (Hamburg, Germany) and Cytek Biosciences (Fremont, CA, USA) are partnering across more than a dozen European countries to expand access to advanced clinical flow cytometry.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.